Instead of just endless combinations of pre-existing cholesterol drugs for a change. It's a sign that your labs are not producing anything.
Mrk will be just fine---buying back stock is one thing--this makes the company stronger for shareholders and maybe a split again???
Agreed just a new spin on existing drugs. Forcast revenue might be $400 mil but its taking revenue away for existing revenue streams.
First of all, cholestral drugs are where it is. So many people are taking them and MRK is making sure they have the mother share---that's what I would expect them to do.
Even if it is two old drugs, the forecasted revenue is at least 400 million in 2014, that's not too bad for two old drugs.
at the cost of its own market share (Vytorin)
MRK has 5 new drugs waiting for FDA approval.
Sentiment: Strong Buy